The ADVIA 2120 Hematology System: Flow Cytometry-Based Analysis of Blood and Body Fluids in the Routine Hematology Laboratory

2005 ◽  
Vol 11 (1) ◽  
pp. 47-61 ◽  
Author(s):  
NEIL HARRIS ◽  
JOLANTA KUNICKA ◽  
ALEXANDER KRATZ
Keyword(s):  
Flow Cytometry ◽  
Body Fluids ◽  
System Flow

Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry

2016 ◽  
Vol 11 (8) ◽  
pp. 1531-1553 ◽  
Author(s):  
Kathrin Moor ◽  
Jehane Fadlallah ◽  
Albulena Toska ◽  
Delphine Sterlin ◽  
Maria L Balmer ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Body Fluids ◽  
Specific Antibodies ◽  
Bacterial Surface

Immunological screening for tumor cells in serous body fluids has added value with the CELL-DYN Sapphire

2014 ◽  
Vol 52 (2) ◽  
Author(s):  
Jeffrey F.W. Keuren ◽  
Johannes J.M.L. Hoffmann ◽  
Mathie P.G. Leers
Keyword(s):  
Flow Cytometry ◽  
Tumor Cells ◽  
Diagnostic Yield ◽  
Body Cavity ◽  
Body Fluids ◽  
Added Value ◽  
Flow Cytometric ◽  
Epithelial Marker ◽  
Effusion Fluid ◽  
Proven Benefit

AbstractConventional cytological examination has limited sensitivity for detecting tumor cells in serous body cavity effusions and therefore, adjuvant techniques are necessary for a reliable diagnosis. Flow cytometry has proven benefit in these circumstances. The aim of our study was to explore the feasibility of CELL-DYN Sapphire, an advanced hematology analyzer with flow cytometric capabilities, for detecting tumor cells in serous body fluids, using CD326 monoclonal antibodies, which are directed against the epithelial marker EpCAM.One hundred and five serous fluids (39 peritoneal and 66 pleural effusions) were analyzed by the CELL-DYN Sapphire using monoclonal antibody combinations CD3/CD19 and CD45/CD326. Of all samples a cytospin preparation was made and microscopically examined; the pathology findings served as a reference.Using a threshold of 1% CD326+ cells, CELL-DYN Sapphire identified nine out of 12 cases with tumor cells in the serous effusions (sensitivity 75%), whereas routine cytology found eight cases (sensitivity 67%). The combination of immunophenotyping and cytology identified all 12 cases with tumor cells in the effusion fluid (sensitivity 100%). The specificities were 92% and 100%, respectively.We demonstrated that it is feasible to run an immunophenotypic assay on CELL-DYN Sapphire for detecting tumor cells in serous body fluids. In addition, this study confirmed that a combination of conventional cytology and flow cytometry had a very high diagnostic yield in cases of carcinomatous effusions.

Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1777-1777
Author(s):  
Vit Pospisil ◽  
Heidi Mocikova ◽  
Magdalena Klanova ◽  
Monika Palickova ◽  
Tomas Kozak ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Cerebrospinal Fluid ◽  
Body Fluids ◽  
Cns Lymphoma ◽  
Transcriptional Level ◽  
Clinical Relapse ◽  
Cns Involvement ◽  
Therapy Efficacy ◽  
Normal Individuals ◽  
Elevated Expression

Abstract Introduction MicroRNAs (miRNAs) are single-stranded non-coding RNAs (21-25nt) that negatively regulate gene expression at post-transcriptional level by blocking translation and mRNA destabilization. Diffuse large B cell lymphomas (DLBCL) overexpress oncogenic microRNAs (including miR-17-92 and miR-155) that regulate tumor growth and spreading. Unlike longer species of RNA, microRNAs are stable and detectable in body fluids including serum/plasma and cerebrospinal fluid (CSF), however their kinetics in body fluids upon course the therapy of DLBCL has not been fully explored. Notably DLBCLs with primary (PCNSL) or secondary CNS involvement display poor prognosis, short overall survival and their current diagnosis and disease monitoring is based on conventiontional methods (magnetic resonance imaging, histopathology, CSF cytology and flow cytometry) with unsatisfactory sensitivity. Aim We investigated abundance of microRNAs in the CSF and sera of DLBCL patients with (N=18) or without (N=30) CNS involvement and compared their levels at diagnosis and during treatment-response phase. Methods Extensive time-points to collect CSF and sera (5-20) were used during and after administration of therapy. Twenty candidate miRs from DLBCL patients were quantitated by TaqMan RT-PCR and their levels adjusted to those of control miRs and normal donors. Results Analysis of CSF at diagnosis revealed that most prominently deregulated miRs (members of oncogenic miR-17-92 cluster and miR-21) were specificaly elevated in both PCNSL (N=11) and systemic lymphomas with CNS involvement (SCNSL, N=7) to similar extent while in systemic lymphomas without CNS involvement (N=30) their levels were significantly lower. Analysis of sera at diagnosis revealed that all SCNSL patients and ∼50% of systemic lymphomas without CNS involvement expressed high levels of the oncomiRs. Surprisingly, also a subset of PCNSL patients had elevated these miRs in the sera and in turn, a subset of systemic lymphomas without CNS involvement showed moderately elevated oncomiRs in the CSF. These data indicate that 1) lymphoma patients with CNS involvement (PCNSL or SCNSL) are characterized by increase of oncogenic microRNAs in CSF, 2) blood brain barrier is likely permissive for miRs in both directions. Next, we investigated the dynamics of abundance of the oncomiRs in CSF upon course of the treatment in 8 patients with PCNSL or SCNSL. In therapy-responders (N=4) the oncomiRs gradually decreased in CSF. However, their levels were not completely normalized as compared to normal individuals. In contrast, refractory lymphomas (N=2) displayed gradual increase of these miRs in CSF regardless the treatment. Interestingly, clinical relapse within CNS as confirmed by MRI and cytology (N=2) was preceded (>3 months) by significant and gradual elevation of miRs in CSF. In systemic lymphoma (N=2) increased levels of studied oncomiRs in CSF preceded the CNS progression. In all cases high levels of miRs in CSF preceded and positively correlated with data from flow cytometry and cytology. Conclusions The measurement of oncomiRs in CSF and sera represents sensitive tool for detection of CNS lymphoma, for monitoring and estimation of therapy efficacy and prediction of the CNS relapse. Furthermore, our data indicate that elevated expression of oncomiRs in CSF and sera in systemic lymphomas may become helpful to predict CNS lymphoma involvement. Grants: GACR305 13-12449P, UNCE204021, PRVOUK: P24/LF1/3, P27/LF1/1, P 27/2012 LF3 Disclosures: Trneny: Roche: Honoraria, Research Funding.

Isolation of Asbestos from Lung Tissue and Sputum

1982 ◽  
Vol 40 ◽  
pp. 330-331
Author(s):  
M. G. Williams ◽  
C. Corn ◽  
R. F. Dodson ◽  
G. A. Hurst
Keyword(s):  
Sodium Hypochlorite ◽  
Lung Tissue ◽  
Body Fluids ◽  
Unknown Etiology ◽  
The Past

During this century, interest in the particulate content of the organs and body fluids of those individuals affected by pneumoconiosis, cancer, or other diseases of unknown etiology developed and concern was further prompted with the increasing realization that various foreign particles were associated with or caused disease. Concurrently particularly in the past two decades, a number of methods were devised for isolating particulates from tissue. These methods were recently reviewed by Vallyathan et al. who concluded sodium hypochlorite digestion was both simple and superior to other digestion procedures.

Flow cytometry using the monoclonal antibody CD10-Pe/Cy5 is a useful tool to identify follicular lymphoma cells

2001 ◽  
Vol 66 (2) ◽  
pp. 100-106 ◽  
Author(s):  
M. Bellido ◽  
E. Rubiol ◽  
J. Ubeda ◽  
O. Lopez ◽  
C. Estivill ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Flow Cytometry ◽  
Follicular Lymphoma ◽  
Lymphoma Cells
Sign in / Sign up

Export Citation Format

Share Document